Minerva Neurosciences, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016. Minerva is a clinical-stage CNS biopharmaceutical company with no approved products and no product revenue. Its portfolio includes MIN-101 (schizophrenia), MIN-202 (insomnia and adjunctive MDD), MIN-117 (MDD), and MIN-301 (Parkinson’s disease).
Financial position and results
| Metric | Q1 2016 | Q1 2015 / prior balance-sheet date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.37 million | $3.96 million |
| General and administrative expense | $2.38 million | $1.92 million |
| Total operating expenses | $7.76 million | $5.88 million |
| Net loss | $8.00 million | $6.09 million |
| Basic and diluted loss per share | $0.29 | $0.31 |
| Net cash used in operating activities | $6.05 million | $4.91 million |
| Cash, cash equivalents and marketable securities | $44.64 million | $32.20 million at Dec. 31, 2015 |
| Total liabilities | $27.78 million | $27.26 million at Dec. 31, 2015 |
At March 31, cash and cash equivalents were $34.82 million; marketable securities were $9.82 million and restricted cash was $0.08 million. Current assets were $45.34 million versus current liabilities of $6.97 million. The company reported no operating profit or meaningful operating margin because it had no revenue. Interest expense was $0.27 million.
Operating expenses increased year over year, principally because of higher MIN-101 and MIN-117 trial spending and higher legal and professional fees. Lower MIN-202 development spending partly offset the R&D increase. Net loss widened, although loss per share declined as weighted-average shares rose to 27.20 million from 19.42 million.
Cash, debt and financing
- Cash from operations was negative $6.05 million. Investing activities provided $8.04 million, mainly from maturities and redemptions of marketable securities.
- Financing activities provided $18.54 million: $17.54 million from warrant exercises and approximately $1.00 million from a private placement to a director. The quarter’s net increase in cash was $20.54 million.
- The company had $10.0 million principal outstanding under its Term A loans, at a fixed 7.05% rate; the loans mature in August 2018 and are secured by substantially all assets other than intellectual property. Principal repayments are expected to be approximately $1.6 million in 2016, $4.9 million in 2017 and $3.5 million in 2018.
- Interest-only payments continue through August 1, 2016, followed by 24 months of principal and interest payments. An additional $5 million Term B tranche remained conditional on clinical milestones; the deadline was extended to June 30, 2016.
Clinical progress, outlook and risks
- MIN-101: Enrollment of 244 patients in the Phase IIb schizophrenia trial was complete; the company expected top-line core-study data in Q2 2016. The six-month extension phase was ongoing, with completion expected in Q3 2016.
- MIN-117: Enrollment of 84 patients in the Phase IIa MDD trial was complete, and top-line data were expected in Q2 2016.
- MIN-202: The company reported positive top-line Phase IIa insomnia results, including a statistically significant sleep-efficiency result versus placebo (p<0.001); no serious adverse events were reported in that trial. It also reported favorable Phase I results in Japanese participants and favorable top-line Phase Ib MDD results. These are company-reported early-stage findings, not evidence of approval or commercial efficacy.
- MIN-301: Development remained preclinical, with further studies planned before an IND or IMPD filing.
- Management estimated that March 31 cash and marketable securities would fund operations into Q2 2017. The company expects continued losses, will need additional capital for later-stage development, and said financing may not be available on acceptable terms; operations could be scaled back or discontinued if funding cannot be obtained.
- The company expected to pay Janssen up to an additional $19 million through Q2 2017 for specified Phase II development. Under the MIN-202 collaboration, Minerva bears 40% of development costs subject to contractual caps; Janssen has certain opt-out and termination rights.
- Material risks include clinical efficacy and safety uncertainty, regulatory and trial delays, dependence on third-party developers and manufacturers, reliance on MTPC and Janssen licenses, potential dilution from future financing, and debt covenants. Management reported no legal proceeding expected to have a material adverse effect, and disclosure controls were effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether MIN-101 and MIN-117 produced the expected Q2 2016 top-line results, and how those results affected subsequent trial plans and spending.
- Whether the company maintained its stated Q2 2017 cash runway after trial costs, the expected Janssen payments and scheduled debt repayments.
- Whether the MIN-117 and MIN-202 milestones required for the potential $5 million Term B loan were met by June 30, 2016.
- The remaining warrant overhang, share dilution from the quarter’s warrant exercises and private placement, and the terms of any subsequent capital raises.
- Whether MIN-202 collaboration obligations, Janssen’s opt-out rights, or any clinical or regulatory developments materially changed the program’s economics or timeline.